A Hematopoietic Score Predicts Survival in Newly Diagnosed Multiple Myeloma Patients.

Risk stratification of multiple myeloma (MM) at diagnosis allows prognostication and drives therapeutic decisions and currently the International staging system (ISS) and the Revised International staging system (RISS) are routinely utilized. Increased red blood cell distribution width (RDW), anemia, and thrombocytopenia have been shown to predict worse progression-free (PFS) and overall survival (OS). We hypothesized that the hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) count may reflect the impact of the tumor cells on the marrow microenvironment and examined its ability to predict outcomes of patients with MM.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Abdullah S. Al Saleh, M Hasib Sidiqi, Angela Dispenzieri, Eli Muchtar, Francis Buadi, Rahma Warsame, Martha Lacy, David Dingli, Nelson Leung, Wilson Gonsalves, Prashant Kapoor, Taxiarchis Kourelis, Morie A. Gertz, Ronald Go, Robert Kyle, S.Vincent Rajkuma Source Type: research